

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Noble James</u> <hr/> (Last) (First) (Middle) SOVEREIGN HOUSE, VISION PARK, HISTON <hr/> (Street) CAMBRIDGE X0 CB24 9BZ <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/01/2018	3. Issuer Name and Ticker or Trading Symbol GW PHARMACEUTICALS PLC [ GWPH ]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	27,500	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Options <sup>(1)</sup>	12/29/2018	12/29/2025	Ordinary Shares	14,479	0.0013 <sup>(2)</sup>	D
Stock Options <sup>(1)</sup>	12/29/2018	12/29/2025	Ordinary Shares	34,061	4.9867 <sup>(2)</sup>	D
Stock Options <sup>(1)</sup>	12/29/2018	12/29/2025	Ordinary Shares	34,061	4.9867 <sup>(2)</sup>	D
Stock Options <sup>(1)</sup>	01/06/2020	01/06/2027	Ordinary Shares	9,168	0.0013 <sup>(2)</sup>	D
Stock Options <sup>(1)(3)</sup>	01/06/2020	01/06/2027	Ordinary Shares	18,636	9.8117	D
Stock Options <sup>(1)</sup>	01/03/2021	01/03/2028	Ordinary Shares	10,740	0.0013 <sup>(2)</sup>	D
Stock Options <sup>(1)(3)</sup>	01/03/2021	01/03/2028	Ordinary Shares	17,676	11.1741	D

**Explanation of Responses:**

- Granted pursuant to the Issuer's Long-Term Incentive Plan.
- Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.302 U.S. Dollars as of September 28, 2018.
- The reported options are options to purchase American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer.

**Remarks:**

/s/ James Noble 10/01/2018  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.